0Y3M Stock Chart & Stats
$9.64
-$0.28(-3.36%)
At close: 4:00 PM EDT
$9.64
-$0.28(-3.36%)
Day’s Range― - ―
52-Week Range$7.89 - $11.67
Previous CloseN/A
Volume6.00
Average Volume (3M)479.00
Market Cap
$450.74M
Enterprise Value$229.30
Total Cash (Recent Filing)$288.19M
Total Debt (Recent Filing)$6.99M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Oct 29, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding51,336,975
10 Day Avg. Volume884
30 Day Avg. Volume479
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.33Price Target Upside173.17% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)$83.99M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage and a sizable equity cushion give Prothena financial resilience while it funds clinical development. Limited debt reduces fixed obligations and refinancing pressure, preserving flexibility to support research programs or withstand delays in partner payments and milestones.
Healthy Gross EconomicsA healthy gross margin indicates that Prothena’s collaboration and licensing activities can generate meaningful economics before research and operating investment. If partnered revenue improves, this gross-profit base could provide operating leverage, although profitability still depends on controlling development spending.
Partnered Pipeline ModelProthena’s focus on antibody-based therapies for misfolded proteins supports a specialized platform centered on significant neurodegenerative disease areas. Partnered programs can provide access to larger biopharmaceutical resources while preserving potential milestone and royalty opportunities.
Bears Say
Declining RevenueRevenue contraction and dependence on irregular partner payments make Prothena’s financial performance difficult to sustain consistently. Timing of milestones, reimbursements, and licensing consideration can create volatility, limiting visibility into recurring revenue growth over the coming quarters.
Deep Operating LossesExtremely negative net and operating margins show that current revenue does not cover the company’s research and operating base. Persistent losses can weaken the funding profile of a clinical-stage biotech and increase reliance on future collaborations, financing, or successful development milestones.
Ongoing Cash BurnNegative operating and free cash flow means Prothena is consuming cash to advance its pipeline rather than internally funding operations. Continued burn can reduce financial flexibility over time, particularly if collaboration proceeds or development milestones arrive later than expected.
Prothena News
0Y3M FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest share price was $7.89 and its highest was $11.67 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $450.74M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Oct 29, 2026 which is in 28 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Aug 06, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.03.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.21.
How many shares outstanding does Prothena have?
Prothena has 51,336,975 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 4.922%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in GB:0Y3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$26.33 (173.17% Upside)
$26.33 (173.17% Upside)
Insider Transactions
Bought Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
0Y3M Stock 12 Month Forecast
Average Price Target
$26.33
▲(173.17% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―